NetworkNewsBreaks – BioAdaptives, Inc. (OTC: BDPT) Announces Aug. 1 Launch of XcellaraHeart Cardiovascular Wellness Supplement
BioAdaptives (OTC: BDPT) announced the upcoming commercial launch of XcellaraHeart(TM), a cardiovascular wellness supplement that combines the company's Xcellara(TM) stem/progenitor cell mobilization formula with Tanshinone IIA, a bioactive compound derived from Danshen root. The company said the Xcellara(TM) base is supported by a randomized, double-blind, placebo-controlled clinical trial that demonstrated an average 268.8% increase in circulating primitive stem/progenitor-type cells after four weeks, while Tanshinone IIA has been studied for its effects on the SDF-1α/CXCR4 signaling pathway associated with cellular trafficking and cardiovascular repair biology. XcellaraHeart(TM) is scheduled to be available for order beginning Aug. 1, 2026, with initial deliveries expected…







